"Clinically predictive preclinical efficacy testing services at your disposal"


Jussi Halleen - CEO, Pharmatest Services

Pharmatest to exhibit and present new data at the AACR 2013 Meeting

[Updated April 9, 2013]

Pharmatest will be attending the key annual event in cancer research, AACR Annual Meeting in Washington DC, USA, April 6-10.

Come and meet us at our exhibit booth (#907) - and if you would like to reserve a meeting with our representative in Washington in advance, please contact us at sales@pharmatest.com.

Pharmatest is also presenting new exciting data on cancer research. We will have altogether five poster presentations at the upcoming show (each poster handout will be available here after the start of the corresponding poster session):

"Inhibiting androgen receptor associated Src signaling with VAL201 inhibits breast cancer growth in an orthotopic xenograft model" (joint presentation with Valirx Plc)

"Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis" (joint presentation with Bayer HealthCare)

"Inhibiting androgen receptor-associated Src signaling by VAL201 inhibits prostate cancer metastasis in an orthotopic mouse model" (joint presentation with Valirx Plc)

"Improved imaging of orthotopic BxPC3 pancreatic adenocarcinoma xenograft using animal PET/CT" (joint presentation with Turku PET Centre, University of Turku)

"Culturing cancer cells on myoma tissue: Development of a novel fully human organotypic 3D invasion model applicable as a preclinical tool for cancer drug development" (joint presentation with University of Oulu)